European Commission Approves Novo Nordisk's Injectable Drug for Obesity

March 24, 2015

(Reuters) - The European Commission has approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects approximately 10 to 30 percent of adults in the European Union.

The injectable drug, to be marketed as Saxenda, is already approved by health regulators in the United States.

The Danish drug maker expects to launch Saxenda in several European markets starting in 2015, it said in a statement. (Reporting by Ole Mikkelsen; Editing by Subhranshu Sahu)


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.